188 related articles for article (PubMed ID: 11705000)
1. The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.
Skarulis MC
Rev Endocr Metab Disord; 2000 Apr; 1(3):147-54. PubMed ID: 11705000
[No Abstract] [Full Text] [Related]
2. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.
Zanotti-Fregonara P; Rubello D; Hindié E
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1397-9. PubMed ID: 18470514
[No Abstract] [Full Text] [Related]
4. Clinical uses of recombinant human thyrotropin.
Gourgiotis L; Skarulis MC
Expert Opin Pharmacother; 2004 Dec; 5(12):2503-14. PubMed ID: 15571468
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
[TBL] [Abstract][Full Text] [Related]
6. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.
Woodmansee WW; Haugen BR
Clin Endocrinol (Oxf); 2004 Aug; 61(2):163-73. PubMed ID: 15272910
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human thyrotropin in the management of thyroid cancer.
McDougall IR; Weigel RJ
Curr Opin Oncol; 2001 Jan; 13(1):39-43. PubMed ID: 11148684
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
9. Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.
Luster M
Acta Oncol; 2006; 45(8):1018-30. PubMed ID: 17118833
[No Abstract] [Full Text] [Related]
10. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
Mernagh P; Suebwongpat A; Silverberg J; Weston A
Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
[TBL] [Abstract][Full Text] [Related]
13. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
Vallejo JA; Muros MA
Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
[TBL] [Abstract][Full Text] [Related]
15. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
16. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.
Driedger AA; Kotowycz N
J Clin Endocrinol Metab; 2004 Feb; 89(2):585-90. PubMed ID: 14764766
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
18. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
19. Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH.
Sugino K; Ito K; Takami H
Endocr J; 2006 Dec; 53(6):723-8. PubMed ID: 16960401
[TBL] [Abstract][Full Text] [Related]
20. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
